Brazil’s Vale reclaims iron ore lead as production surge bolsters investor confidence
Vale announced its operational data for the fourth quarter of 2025 on Tuesday, which received a broadly positive reception among market analysts amid
US stocks open in the green: S&P breaches 7,000, Nasdaq climbs 0.7%
US equities advanced on Wednesday, with the S&P 500 reaching the 7,000 level for the first time, as investors positioned ahead of the
KuCoin partners with Tour de France Champion Tadej Pogačar in trust-led crypto collaboration
KuCoin announced a partnership with Tadej Pogačar, the four-time Tour de France champion, and it doesn’t seem to be a typical athlete sponsorship
Brazil’s Vale reclaims iron ore lead as production surge bolsters investor confidence
Vale announced its operational data for the fourth quarter of 2025 on Tuesday, which received a broadly positive reception among market analysts amid
US stocks open in the green: S&P breaches 7,000, Nasdaq climbs 0.7%
US equities advanced on Wednesday, with the S&P 500 reaching the 7,000 level for the first time, as investors positioned ahead of the
KuCoin partners with Tour de France Champion Tadej Pogačar in trust-led crypto collaboration
KuCoin announced a partnership with Tadej Pogačar, the four-time Tour de France champion, and it doesn’t seem to be a typical athlete sponsorship
Crypto
Hyperliquid (HYPE) Ignites a 22% Rally: Can Bulls Chase $30 as Volatility Creeps In?
Hyperliquid rockets 22%, trading at $27. HYPE’s trading volume has exploded by 98%. A 1.62% spike in the crypto market has brought in
Crypto
Grayscale Updates S-1 Filing for Sui Staking ETF as SUI Trades Near $1.44
Grayscale has amended its S-1 filing with the U.S. SEC for a proposed Sui Staking ETF (GSUI). SUI is trading at $1.44, with
Investing
Homerun Resources Inc. Announces Five-Fold Increase in Solar Glass Offtake with Sengi Solar from 20,000 to 100,000 Tonnes per Year Priced at USD 750 per Tonne
Homerun Resources Inc. (TSXV: HMR,OTC:HMRFF) (OTCQB: HMRFF) (‘Homerun’ or the ‘Company’) is pleased to announce that the Company has signed an amendment to its non-binding
Investing
Expansion of SVN-015 into Depression Following Positive Preclinical Data
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (‘CNS’) disorders, announces the expansion of